These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 28873508)

  • 21. C-reactive protein is superior to fecal biomarkers for evaluating colon-wide active inflammation in ulcerative colitis.
    Ishida N; Higuchi T; Miyazu T; Tamura S; Tani S; Yamade M; Iwaizumi M; Hamaya Y; Osawa S; Furuta T; Sugimoto K
    Sci Rep; 2021 Jun; 11(1):12431. PubMed ID: 34127687
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fecal Calprotectin in Assessing Endoscopic and Histological Remission in Patients with Ulcerative Colitis.
    Mak WY; Buisson A; Andersen MJ; Lei D; Pekow J; Cohen RD; Kahn SA; Pereira B; Rubin DT
    Dig Dis Sci; 2018 May; 63(5):1294-1301. PubMed ID: 29468374
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The value of fecal calprotectin as a marker of intestinal inflammation in patients with ulcerative colitis.
    Önal İK; Beyazit Y; Şener B; Savuk B; Özer Etık D; Sayilir A; Öztaş E; Torun S; Özderın Özın Y; Tunç Demırel B; Ülker A; Dağli Ü
    Turk J Gastroenterol; 2012; 23(5):509-14. PubMed ID: 23161295
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The sensitivity of fecal calprotectin in predicting deep remission in ulcerative colitis.
    Carlsen K; Riis LB; Elsberg H; Maagaard L; Thorkilgaard T; Sørbye SW; Jakobsen C; Wewer V; Florholmen J; Goll R; Munkholm P
    Scand J Gastroenterol; 2018; 53(7):825-830. PubMed ID: 29968483
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of treatment outcome and relapse in inflammatory bowel disease.
    Kato J; Yoshida T; Hiraoka S
    Expert Rev Clin Immunol; 2019 Jun; 15(6):667-677. PubMed ID: 30873890
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Accuracy of Faecal Immunochemical Test to Predict Endoscopic and Histological Healing in Ulcerative Colitis: A Prospective Study Based on Validated Histological Scores.
    Shi HY; Chan FKL; Chan AWH; Higashimori A; Kyaw M; Ching JYL; Luk AKC; Wong SH; Wu JCY; Sung JJY; Ng SC
    J Crohns Colitis; 2017 Sep; 11(9):1071-1077. PubMed ID: 28881876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The novel latex agglutination turbidimetric immunoassay system for simultaneous measurements of calprotectin and hemoglobin in feces.
    Hiraoka S; Takashima S; Inokuchi T; Nakarai A; Takahara M; Harada K; Seki Y; Watanabe K; Kato J; Okada H
    Intest Res; 2019 Apr; 17(2):202-209. PubMed ID: 30541228
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of disease duration on fecal biomarkers in ulcerative colitis: a prospective cohort study.
    Ishida N; Kaneko M; Asai Y; Miyazu T; Tamura S; Tani S; Yamade M; Iwaizumi M; Hamaya Y; Osawa S; Furuta T; Sugimoto K
    BMC Gastroenterol; 2022 Sep; 22(1):420. PubMed ID: 36109718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heat shock transcription factor 2 predicts mucosal healing and promotes mucosal repair of ulcerative colitis.
    Wen Y; Niu J; Zhang F; Wu J; Li M; Sun Y; Wang W; Xia S; Tan Y; Wang K; Miao Y
    Scand J Gastroenterol; 2020 Jun; 55(6):677-686. PubMed ID: 32538201
    [No Abstract]   [Full Text] [Related]  

  • 30. Significance of Conducting 2 Types of Fecal Tests in Patients With Ulcerative Colitis.
    Naganuma M; Kobayashi T; Nasuno M; Motoya S; Kato S; Matsuoka K; Hokari R; Watanabe C; Sakamoto H; Yamamoto H; Sasaki M; Watanabe K; Iijima H; Endo Y; Ichikawa H; Ozeki K; Tanida S; Ueno N; Fujiya M; Sako M; Takeuchi K; Sugimoto S; Abe T; Hibi T; Suzuki Y; Kanai T
    Clin Gastroenterol Hepatol; 2020 May; 18(5):1102-1111.e5. PubMed ID: 31394288
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serial semi-quantitative measurement of fecal calprotectin in patients with ulcerative colitis in remission.
    Garcia-Planella E; Mañosa M; Chaparro M; Beltrán B; Barreiro-de-Acosta M; Gordillo J; Ricart E; Bermejo F; García-Sánchez V; Piqueras M; Llaó J; Gisbert JP; Cabré E; Domènech E;
    Scand J Gastroenterol; 2018 Feb; 53(2):152-157. PubMed ID: 29189092
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined Use of Common Fecal and Blood Markers for Detection of Endoscopically Active Inflammatory Bowel Disease.
    Mak LY; Tong TSM; Cheung KS; Chen LJ; Lui KL; Lau KS; Leung WK
    Clin Transl Gastroenterol; 2020 Mar; 11(3):e00138. PubMed ID: 32132451
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical Diagnostics of Fecal Calprotectin: a Comparative Study of Actim® Calprotectin and LIAISON® Calprotectin.
    Miettinen JA; Vuolteenaho O; Hedberg P
    Clin Lab; 2022 Jan; 68(1):. PubMed ID: 35023670
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extent of disease affects the usefulness of fecal biomarkers in ulcerative colitis.
    Sakuraba A; Nemoto N; Hibi N; Ozaki R; Tokunaga S; Kikuchi O; Minowa S; Mitsui T; Miura M; Saito D; Hayashida M; Miyoshi J; Matsuura M; Yoneyama M; Ohnishi H; Hisamatsu T
    BMC Gastroenterol; 2021 May; 21(1):197. PubMed ID: 33933033
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediction of endoscopic disease activity in ulcerative colitis by two different assays for fecal calprotectin.
    Kristensen V; Klepp P; Cvancarova M; Røseth A; Skar V; Moum B
    J Crohns Colitis; 2015 Feb; 9(2):164-9. PubMed ID: 25518057
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Eicosapentaenoic Acid Reduces Fecal Levels of Calprotectin and Prevents Relapse in Patients With Ulcerative Colitis.
    Scaioli E; Sartini A; Bellanova M; Campieri M; Festi D; Bazzoli F; Belluzzi A
    Clin Gastroenterol Hepatol; 2018 Aug; 16(8):1268-1275.e2. PubMed ID: 29391271
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessing the Correlation of Fecal Calprotectin and the Clinical Disease Activity Index in Patients With Ulcerative Colitis.
    Amiriani T; Besharat S; Dadjou M; Roshandel G; Mirkarimi H; Salamat F; Joshaghani H
    Gastroenterol Nurs; 2018; 41(3):201-205. PubMed ID: 29847394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory Bowel Disease.
    Abej E; El-Matary W; Singh H; Bernstein CN
    Can J Gastroenterol Hepatol; 2016; 2016():2483261. PubMed ID: 27774443
    [No Abstract]   [Full Text] [Related]  

  • 39. Accuracy of advanced endoscopy and fecal calprotectin for prediction of relapse in ulcerative colitis: a prospective study.
    Jauregui-Amezaga A; López-Cerón M; Aceituno M; Jimeno M; Rodríguez de Miguel C; Pinó-Donnay S; Zabalza M; Sans M; Ricart E; Ordás I; González-Suárez B; Cuatrecasas M; Llach J; Panés J; Pellise M
    Inflamm Bowel Dis; 2014 Jul; 20(7):1187-93. PubMed ID: 24874457
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rapid Fecal Calprotectin Testing Predicts Mucosal Healing Better than C-reactive Protein and Serum Tumor Necrosis Factor α in Patients with Ulcerative Colitis.
    Voiosu T; Benguş A; Bălănescu P; Dinu R; Voiosu A; Băicuş C; Mateescu B
    Rom J Intern Med; 2015; 53(3):253-60. PubMed ID: 26710501
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.